Abstract
Camptothecins are cytotoxic agents with a wide spectrum of antitumor activity. The unique mechanism of action, the impressive preclinical efficacy and the clinical success of irinotecan and topotecan have stimulated intensive efforts to identify novel analogues. The development of novel camptothecins was recently rationalized on the basis of the detailed knowledge of mechanism of drug-target interaction and was aimed to overcome the major limitations of these drugs (i.e. lactone ring instability and reversibility of topoisomerase I-DNA cleavage complexes). The development of novel series of analogues (7-substituted camptothecins, silatecans and homocamptothecins) resulted in identification of promising compounds, which are currently in clinical development. Considering the lack of precise correlations between preclinical activity and clinical efficacy of camptothecins, the potential advantages of novel analogs in clinical therapy remains to be documented. However, a rational basis for drug selection and development is now provided by the recognition of major limitations of these agents and by a detailed knowledge of multiple interactions between drug, cellular target and serum albumin. Inhibition of the nuclear enzyme DNA topoisomerase I has proven to be a promising strategy in the design of antitumor agents, in spite of a limited cellular basis of selectivity in cytotoxic action of camptothecins (i.e., overexpression of the target enzyme in tumor cells, and increased sensitivity of proliferating cells). The interest in topoisomerase I as a therapeutic target promoted various efforts to identify other chemotypes effecti ve as topoisomerase inhibitors and chemical / modelling efforts to rationally design specific analogs among known inhibitors. Additional approaches, including drug delivery / formulation, optimization of dose / schedule and route of administration, are expected to improve the therapy with camptothecins and other inhibitors.
Keywords: antitumor agents, Topoisomerase I, Camptothecin
Current Pharmaceutical Design
Title: Current Status and Perspectives in the Development of Camptothecins
Volume: 8 Issue: 27
Author(s): Franco Zunino, Sabrina Dallavalle, Diletta Laccabue, Giovanni Beretta, Lucio Merlini and Graziella Pratesi
Affiliation:
Keywords: antitumor agents, Topoisomerase I, Camptothecin
Abstract: Camptothecins are cytotoxic agents with a wide spectrum of antitumor activity. The unique mechanism of action, the impressive preclinical efficacy and the clinical success of irinotecan and topotecan have stimulated intensive efforts to identify novel analogues. The development of novel camptothecins was recently rationalized on the basis of the detailed knowledge of mechanism of drug-target interaction and was aimed to overcome the major limitations of these drugs (i.e. lactone ring instability and reversibility of topoisomerase I-DNA cleavage complexes). The development of novel series of analogues (7-substituted camptothecins, silatecans and homocamptothecins) resulted in identification of promising compounds, which are currently in clinical development. Considering the lack of precise correlations between preclinical activity and clinical efficacy of camptothecins, the potential advantages of novel analogs in clinical therapy remains to be documented. However, a rational basis for drug selection and development is now provided by the recognition of major limitations of these agents and by a detailed knowledge of multiple interactions between drug, cellular target and serum albumin. Inhibition of the nuclear enzyme DNA topoisomerase I has proven to be a promising strategy in the design of antitumor agents, in spite of a limited cellular basis of selectivity in cytotoxic action of camptothecins (i.e., overexpression of the target enzyme in tumor cells, and increased sensitivity of proliferating cells). The interest in topoisomerase I as a therapeutic target promoted various efforts to identify other chemotypes effecti ve as topoisomerase inhibitors and chemical / modelling efforts to rationally design specific analogs among known inhibitors. Additional approaches, including drug delivery / formulation, optimization of dose / schedule and route of administration, are expected to improve the therapy with camptothecins and other inhibitors.
Export Options
About this article
Cite this article as:
Zunino Franco, Dallavalle Sabrina, Laccabue Diletta, Beretta Giovanni, Merlini Lucio and Pratesi Graziella, Current Status and Perspectives in the Development of Camptothecins, Current Pharmaceutical Design 2002; 8 (27) . https://dx.doi.org/10.2174/1381612023392801
DOI https://dx.doi.org/10.2174/1381612023392801 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Impact of Drug Metabolism/Pharmacokinetics and their Relevance Upon Taxus-based Drug Development
Current Drug Metabolism Carboranylporphyrins for Boron Neutron Capture Therapy of Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients
Current Pharmaceutical Design Anti-Cancer Therapy: Targeting the Mevalonate Pathway
Current Cancer Drug Targets Regulation by IFN-α/IFN-γ Co-Formulation (HerberPAG<sup>®</sup>) of Genes Involved in Interferon-STAT-Pathways and Apoptosis in U87MG
Current Topics in Medicinal Chemistry N6-Methyladenosine-Related RNA Signature Predicting the Prognosis of Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Functional PLGA NPs for Oral Drug Delivery: Recent Strategies and Developments
Mini-Reviews in Medicinal Chemistry Cancer Preventive Phytochemicals as Speed Breakers in Inflammatory Signaling Involved in Aberrant COX-2 Expression
Current Cancer Drug Targets What they are, How they Work and Why they do What they do? The Story of SV40-derived Gene Therapy Vectors and What They Have to Offer
Current Gene Therapy Nanoparticles as Novel Carrier for Brain Delivery: A Review
Current Pharmaceutical Design 99mTc-labeling of Peptidomimetic Antagonist to Selectively Target αvβ3 Receptor-Positive Tumor: Comparison of PDA and EDDA as Co-Ligands
Current Radiopharmaceuticals Patent Selections:
Recent Patents on Inflammation & Allergy Drug Discovery Analogs of Cinnamic Acid Benzyl Amide As Nonclassical Inhibitors of Activated JAK2 Kinase
Current Cancer Drug Targets Conjugation Approaches for Construction of Aptamer-Modified Nanoparticles for Application in Imaging
Current Topics in Medicinal Chemistry NMR in Metabolic Profiles of Neural Stem/Progenitor Cells: Current Status and Relevant Problems
Current Medical Imaging Breast Cancer Resistance Protein and P-Glycoprotein in Brain Cancer: Two Gatekeepers Team Up
Current Pharmaceutical Design The Past, Current Studies and Future of Organometallic <sup>99m</sup>Tc(CO)3 Labeled Peptides and Proteins
Current Pharmaceutical Design Development of Selective High Affinity Antagonists, Agonists, and Radioligands for the P2Y1 Receptor
Combinatorial Chemistry & High Throughput Screening A Role for the Inflammatory Mediators Cox-2 and Metalloproteinases in Cancer Stemness
Anti-Cancer Agents in Medicinal Chemistry Novel Biomarkers of microRNAs in Gastric Cancer: An Overview from Diagnosis to Treatment
MicroRNA